|
|
ASH 2005 Webcast
The IMF is pleased to provide you with a broad sampling of myeloma presentations and posters from the 2005 annual meeting of the American Society of Hematology in San Diego, California. We hope you will find this material informative and useful.
|
|
Velcade (Bortezamib)
|
|
|
Dr. Paul Richardson of the Dana Farber Cancer Institute provides an update on the Velcade APEX trial |
|
|
|
|
Dr. San Miguel presented data on the rate of peripheral neuropathy in the APEX Velcade trial |
|
|
|
|
Dr. Jagannath’s reports on a multi-center trial for newly diagnosed myeloma patients receiving frontline therapy with Velcade |
|
|
|
|
Dr. Cavenagh presented results of a trial combining Velcade with another chemotherapy agent, melphalan, in patients with relapsed/refractory disease |
|
|
|
|
|
Dr. San Miguel presented interim data on the ongoing PETHEMA study of melphalan, prednisone, and Velcade in elderly, previously untreated myeloma patients |
|
|
|
|
|
Dr. Cavenagh reported on his ongoing trial combining Velcade, Adriamycin, and dexamethasone (PAD) in previously untreated myeloma |
|
|
|
|
Dr. Vij addressed the increased incidence of herpes zoster (shingles) with Velcade in the peri-transplant setting and preventative measures that can be taken to avoid this complication |
|
Revlimid (Lenalidomide)
|
|
|
Dr. Palumbo reported on the results of a Phase II trial of melphalan/prednisone/revlimid |
|
Thalomid (Thalidomide)
|
|
|
Dr. Ludwig presented an interim analysis of an ongoing trial of thal/dex versus MP in 205 elderly (median age 72), newly diagnosed patients with myeloma |
|
|
|
|
Dr. Facon reports on an interim analysis of the ongoing Intergroup Francais du Myelome (IFN) 99-06 clinical trial comparing melphalan–prednisone (MP), melphalan-prednisone-thalidomide (MPT), and stem cell transplant with reduced-dose-chemotherapy (melphalan 100 mg/m2 or “mel 100”) in elderly (65-75 years of age), newly diagnosed myeloma patients |
|
|
back
print
back to top